MX2022003707A - Compuestos de pirazolopiridina como inhibidores selectivos de quinasa btk. - Google Patents

Compuestos de pirazolopiridina como inhibidores selectivos de quinasa btk.

Info

Publication number
MX2022003707A
MX2022003707A MX2022003707A MX2022003707A MX2022003707A MX 2022003707 A MX2022003707 A MX 2022003707A MX 2022003707 A MX2022003707 A MX 2022003707A MX 2022003707 A MX2022003707 A MX 2022003707A MX 2022003707 A MX2022003707 A MX 2022003707A
Authority
MX
Mexico
Prior art keywords
kinase inhibitors
btk kinase
selective btk
pyrazolopyridine compounds
disclosed
Prior art date
Application number
MX2022003707A
Other languages
English (en)
Inventor
Shuhui Chen
Guoping Hu
Jian Li
Wei Zheng
Chunli Shen
xia wei Wei
Chengde Wu
Ning Jiang
Original Assignee
Jumbo Drug Bank Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jumbo Drug Bank Co Ltd filed Critical Jumbo Drug Bank Co Ltd
Publication of MX2022003707A publication Critical patent/MX2022003707A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se dan a conocer una clase de compuestos inhibidores de quinasa BTK con alta actividad y alta selectividad y el uso de los mismos en la preparación de un fármaco para tratar enfermedades relacionadas con la diana BTK. Específicamente, se dan a conocer un compuesto mostrado como fórmula (I) y un isómero y una sal farmacéuticamente aceptable del mismo.(ver formula).
MX2022003707A 2019-09-26 2020-09-25 Compuestos de pirazolopiridina como inhibidores selectivos de quinasa btk. MX2022003707A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910919180 2019-09-26
CN202010330226 2020-04-24
PCT/CN2020/117690 WO2021057893A1 (zh) 2019-09-26 2020-09-25 作为选择性btk激酶抑制剂的吡唑并吡啶类化合物

Publications (1)

Publication Number Publication Date
MX2022003707A true MX2022003707A (es) 2022-06-23

Family

ID=75164834

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003707A MX2022003707A (es) 2019-09-26 2020-09-25 Compuestos de pirazolopiridina como inhibidores selectivos de quinasa btk.

Country Status (18)

Country Link
US (1) US11739090B2 (es)
EP (1) EP4036095B1 (es)
JP (1) JP7213604B2 (es)
KR (1) KR102500569B1 (es)
CN (1) CN114450289B (es)
AU (1) AU2020355845B2 (es)
BR (1) BR112022005729A2 (es)
CA (1) CA3152587C (es)
DK (1) DK4036095T3 (es)
FI (1) FI4036095T3 (es)
HR (1) HRP20240283T1 (es)
LT (1) LT4036095T (es)
MX (1) MX2022003707A (es)
PL (1) PL4036095T3 (es)
PT (1) PT4036095T (es)
RS (1) RS65239B1 (es)
SI (1) SI4036095T1 (es)
WO (1) WO2021057893A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022199591A1 (zh) * 2021-03-23 2022-09-29 成都嘉葆药银医药科技有限公司 一种氟取代的吡啶并吡唑类化合物的晶型及其制备方法
WO2024022234A1 (zh) * 2022-07-28 2024-02-01 成都嘉葆药银医药科技有限公司 吡唑并吡啶类化合物在制备治疗包括中枢神经系统疾病的btk相关疾病的药物中的用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2561875A3 (en) * 2007-03-28 2013-06-12 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20150152115A1 (en) * 2007-12-27 2015-06-04 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
WO2011023584A2 (en) 2009-08-27 2011-03-03 Polymers Crc Ltd. Nano silver-zinc oxide composition
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
WO2014113942A1 (en) * 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
US20160113893A1 (en) * 2013-06-12 2016-04-28 Proximagen Limited New therapeutic uses of enzyme inhibitors
US9637486B2 (en) 2013-12-20 2017-05-02 Merck Sharp & Dohme Corp. Btk inhibitors
US9834554B2 (en) * 2013-12-20 2017-12-05 Merck Sharp & Dohme Corp. BTK inhibitors
CN105017256A (zh) * 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
CN105085474B (zh) * 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
CN105399756B (zh) * 2014-09-05 2019-06-25 广东东阳光药业有限公司 Btk抑制剂及其用途
WO2016106652A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Biarylether imidazopyrazine btk inhibitors
WO2016106627A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
TW201718572A (zh) * 2015-06-24 2017-06-01 普林斯匹亞生物製藥公司 酪胺酸激酶抑制劑
CN105753863B (zh) * 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 氧代二氢咪唑并吡啶类化合物及其应用
EP3405192A4 (en) 2016-01-21 2019-07-03 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. INHIBITORS OF BRUTON TYROSINE KINASE
EP3426637B1 (en) 2016-03-11 2022-02-09 Angel Pharmaceutical Co., Ltd. Compounds and methods for modulating bruton's tyrosine kinase
US11186578B2 (en) * 2016-08-17 2021-11-30 Shenzhen Targetrx, Inc. Substituted pyrrolo[3,2-d]pyrimidines and pyrazolo[4,3-d]pyrimidines as tyrosine kinase inhibitors
JOP20190113A1 (ar) 2016-11-18 2019-05-15 Biocad Joint Stock Co مثبطات بروتون تيروزين كيناز
CN106588937B (zh) * 2017-01-16 2018-09-21 东莞市真兴贝特医药技术有限公司 咪唑并吡嗪类化合物及其制备方法和应用
CN110272416A (zh) * 2018-03-14 2019-09-24 武汉宇科源医药生物科技有限公司 吡唑并[3,4-c]吡啶-7-胺衍生物及其制备方法和应用

Also Published As

Publication number Publication date
FI4036095T3 (fi) 2024-02-14
CA3152587C (en) 2023-05-23
KR20220061262A (ko) 2022-05-12
BR112022005729A2 (pt) 2022-06-21
CN114450289B (zh) 2024-01-02
EP4036095A1 (en) 2022-08-03
PT4036095T (pt) 2024-02-19
CN114450289A (zh) 2022-05-06
PL4036095T3 (pl) 2024-04-15
CA3152587A1 (en) 2021-04-01
US20220324864A1 (en) 2022-10-13
LT4036095T (lt) 2024-03-25
RS65239B1 (sr) 2024-03-29
SI4036095T1 (sl) 2024-04-30
JP2022542196A (ja) 2022-09-29
AU2020355845B2 (en) 2023-04-06
EP4036095A4 (en) 2022-12-07
JP7213604B2 (ja) 2023-01-27
KR102500569B1 (ko) 2023-02-16
WO2021057893A1 (zh) 2021-04-01
DK4036095T3 (da) 2024-03-04
HRP20240283T1 (hr) 2024-05-10
US11739090B2 (en) 2023-08-29
AU2020355845A1 (en) 2022-05-19
EP4036095B1 (en) 2024-01-31

Similar Documents

Publication Publication Date Title
EA201792116A1 (ru) Ингибитор янус-киназы
MX2022001421A (es) Compuesto tetracíclico, método de preparación y uso del mismo.
MX2022007915A (es) Compuestos de benzopirazol y analogos de estos.
MX2019003143A (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
EA201791576A1 (ru) Ингибитор jak
CL2023001369A1 (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
MX2017012295A (es) Derivados formilados n-heterociclicos como inhibidores de fgfr4.
AR122351A1 (es) Derivados de metilquinazolinona como inhibidores de braf
MX2022003707A (es) Compuestos de pirazolopiridina como inhibidores selectivos de quinasa btk.
MY194873A (en) Fused Bicyclic Heteroaryl Derivatives Having Activity as Phd Inhibitors
MX2019003317A (es) Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
MX2021007247A (es) Derivados de rapamicina.
UY36123A (es) Derivados de carboxamida
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
MY186598A (en) Carboxamide derivatives
EA201991355A1 (ru) Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта
PH12021550406A1 (en) Fused ring derivative used as fgfr4 inhibitor
MX2022004713A (es) Derivados de tiofeno como inhibidores de xantina oxidasa y aplicacion de los mismos.
MX2021012499A (es) Inhibidores mejorados del complejo de activación transcripcional notch y métodos para el uso de estos.
MX2018015990A (es) Compuestos terapeuticos.
MX2021014194A (es) Derivados de piridopirimidina y composiciones farmacéuticas, para su uso para prevenir o tratar enfermedades relacionadas con pi3 cinasa, que comprenden los mismos como principio activo.
EA201991932A1 (ru) Производное азитидина